FOXO4-DRI: senolytics are a real field, so why is this one nowhere?

FOXO4-DRI comes from senescent-cell-clearance work, which is a serious and well-funded research area. Yet the page is evidence: none.

Is the compound behind the field, or is the field behind its own press?

Some of both, and the distinction is worth keeping.

Senolytics as a concept has real support — clearing senescent cells improves multiple outcomes in animal models, reproducibly, across groups. That is much better evidence than most things in the longevity category get.

FOXO4-DRI specifically is one candidate molecule from that field, and being from a promising field is not the same as being a promising molecule. Most candidates in any field do not make it. The peptide-marketing move is to cite the field's evidence for the molecule's page.

That is the same error as citing thymosin beta-4's trials for TB-500, one level up.

Borrowed credibility, at the level of the research programme rather than the molecule. Noted.

It is a very effective move because everything cited is true. The field's results are real, the molecule is genuinely from that field, and the inference between them is the only false step — and it is the one nobody states out loud.